MorphoSys AG at Goldman Sachs Healthcare Conference Transcript
Okay. Good afternoon, everyone. I'm Rajan Sharma. I'm the European biotech analyst here at Goldman Sachs. Pleased that we have MorphoSys at the conference today, and we have Jean-Paul Kress, who's CEO. So yes, thank you for joining.
Questions & Answers
Jean-Paul, do you want to maybe make some introductory statements? Obviously, there's been a bit of change at the company over the last 12 months or so. So, maybe you could just give us a high-level overview of what's been going on and where you are today?
Sure. Well, first of all, thank you very much for having me and have the opportunity to share on the great progress we're making at MorphoSys. So yes, a lot of changes for good actually over the last few years actually because we pivoted MorphoSys from a fee-for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |